Harvard University
Researchers detail new studies and findings in the area of cardiology
Published in Cancer Law Weekly, April 8th, 2006
Study 1: Implantable cardioverter defibrillator (ICD) implantation can be performed without epicardial patches or transvenous high-energy leads in the pediatric and congenital heart disease (CHD) population using individualized techniques.
Investigators in the United States report, "In pediatric and congenital heart disease patients, transvenous ICD implantation may be limited secondary to patient size, venous, or cardiac anatomy. Epicardial patches require a thoracotomy, and may lead to a restrictive pericardial process. Because of these issues, we have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
Source: Cancer Law Weekly (2006-04-08)
More Articles from Cancer Law Weekly
- Advaxis, Inc.
Advaxis receives approvals to commence study of Listeria vaccine for cervical cancer - Arius Research, Inc.
U.S. patent issued to Arius Research for anti-CD63 antibody for cancer treatment - Braintree Laboratories, Inc.
Braintree Laboratories in-licenses rights to chemoprevention agent against colorectal cancer - Dana-Farber Cancer Institute, Boston
Ovarian cancer patients treated by gynecologic oncologists had better outcomes - DiagnoCure, Inc.
DiagnoCure wins U.S. patent for PCA3 - John Wiley & Sons, Inc.
Disclosing study outcomes to participants may backfire - More from this issue of Cancer Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
